Abiraterone acetate and prednisolone for high-risk, hormone-sensitive metastatic prostate cancer (adults) NHS England » Abiraterone acetate and prednisolone for high-risk, hormone-sensitive metastatic prostate cancer (adults) [2424] Skip to main content Cookies on the NHS England websiteWe’ve put some small files called cookies on your device to make our site work. We’d also like to use Search Menu * About us * Our work * Commissioning * Get involved Abiraterone acetate and prednisolone for high-risk, hormone-sensitive metastatic prostate cancer (adults) [2424]Document first published: 13 December 2024 Page updated: 13 December 2024 Topic: Commissioning, Medicine, Specialised commissioning Publication type: Policy or strategy The proposition is: abiraterone acetate and prednisolone
Daily low-dose prednisolone to prevent relapse of steroid-sensitive nephrotic syndrome in children with an upper respiratory tract infection: PREDNOS2 RCT Daily low-dose prednisolone to prevent relapse of steroid-sensitive nephrotic syndrome in children with an upper respiratory tract infection: PREDNOS2 RCT * Text only * * Home * Journals * * Other NIHR research * * For authors {{metadata .Issue }} * Toolkit * * Download report PDF * Download report documents * Download report documents * * Disclosure of interest * * * Download report XML * * Citation Tools * Print * * * * Responses to this report (0) * Permissions information View ProjectSix days of daily low-dose prednisolone during an upper respiratory tract
Niraparib and Abiraterone Acetate (Akeega) - With prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA mutated (germline and/or somatic) mCRPC Return to Article DetailsNiraparib and Abiraterone Acetate (Akeega)
Olaparib (Lynparza) in combination with abiraterone and prednisone or prednisolone for the treatment of metastatic castration-resistant prostate cancer (mCRPC) ENGLISH | DEUTSCH ATOM RSS 1.0 RSS 2.0SIMPLE SEARCHADVANCED SEARCHHELPSERVICESLOGINBrowseTypeSubjectAuthor / EditorInstitutionYear AIHTA - Publications - Search - Olaparib (Lynparza®) in combination with abiraterone and prednisone or prednisolone for the treatment of metastatic castration-resistant prostate cancer (mCRPC)Rothschedl, E. and Wolf, S. (2023): Olaparib (Lynparza®) in combination with abiraterone and prednisone or prednisolone for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Oncology Fact Sheet Nr. 117. PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder
Switching between oral prednisolone and IV hydrocortisone SPS - Specialist Pharmacy ServiceAbout Log in RegisterNHSGuidanceEventsPodcastsPlanningTrainingPublicationsTools SearchCOVID-19PGDsAdministeringCautions and contraindicationsDosingSwitchingMore Switching between oral prednisolone and IV hydrocortisonePublished 29 September 2023Topics: Hydrocortisone · Prednisolone · SwitchingSwitching between oral prednisolone and intravenous (IV) hydrocortisone requires care due to the risk of adrenal insufficiency or adrenal crisis.ContentsReason for switchingConsiderations for switchingFormulations availableGlucocorticoid activityHydrocortisone bioavailabilityClinical considerationsConverting dosesDetermine the oral prednisolone doseConvert to IV hydrocortisoneSelect the correct IV hydrocortisone
The effect of prednisolone and a short-term prednisolone discontinuation for the diagnostic accuracy of FDG-PET/CT in polymyalgia rheumatica-a prospective study of 101 patients. 2-[18F]Fluoro-2-deoxy-D-glucose (FDG)-positron emission tomography (PET)/computed tomography (CT) has been suggested as an imaging modality to diagnose polymyalgia rheumatica (PMR). However, the applicability of FDG-PET /CT remains unclear, especially following glucocorticoid administration. This study aimed to investigate the diagnostic accuracy of FDG-PET/CT before and during prednisolone treatment, as well as following short-term prednisolone discontinuation. Treatment naïve suspected PMR patients were clinically diagnosed at baseline and subsequently had an FDG-PET/CT performed. Patients diagnosed with PMR were
Granulocyte Colony-Stimulating Factor Improves Prednisolone Responsiveness and 90-Day Survival in Steroid-Eligible Severe Alcohol-Associated Hepatitis: The GPreAH Study a Randomized Trial Severe alcohol-associated-hepatitis(SAH) carries high one-month mortality. Corticosteroids provide a modest 28 day but not 90-day survival benefit, due to development of infections and organ failures . Granulocyte colony stimulating factor(GCSF) has shown promise in SAH patients by its immunomodulatory and regenerative capabilities. We studied the safety and efficacy of combination(GCSF+Prednisolone, GPred) therapy in management of steroid eligible SAH patients. Steroid eligible patients with SAH(mDF scores 32- 90) were randomized to receive Prednisolone(GrA, n=42), GPred(GrB, n=42) or GCSF alone(GrC, n
Prednisolone Versus Colchicine for Acute Gout in Primary Care (COPAGO): protocol for a two-arm multicentre, pragmatic, prospective, randomized, double-blind, controlled clinical trial of prednisolone and colchicine for non-inferiority with a parallel gro Gout is the most common form of rheumatic disease in which monosodium urate crystals are deposited in the joints followed by acute inflammatory reactions. There are various approved drugs that can be prescribed for pain relief during an acute gout attack. However, to date, no direct comparison of efficacy of colchicine and prednisolone for the treatment of acute gout attacks has been investigated. Furthermore, the majority of previous research studies were not only conducted in tertiary centres but also excluded patients with common comorbidities
Infections in Standard or Tapered Dose of Prednisolone for Alcohol-Associated Hepatitis: A Randomized Trial (STASH Trial). Current guidance recommends a 40-mg dose of prednisolone (or equivalent) for severe alcohol-associated hepatitis (AAH), while infections are not uncommon in them. The benefits of a rapid prednisolone tapering regimen in mitigating infection in patients with AAH are unknown . The primary objective was to assess the incidence of infection by day 90. The key secondary objectives were the incidence of mortality, acute kidney injury (AKI), readmissions rate and adverse events. In this multicenter randomized clinical trial, patients with severe AAH were included from 15/03/2023 to 28/08/2024. Participants were randomly assigned to receive a standard fixed prednisolone dose (40 mg/day
Food effects and pharmacokinetic evaluation of oral single-dose prednisone acetate and prednisolone in healthy Chinese subjects. To assess the food effects and pharmacokinetic profile of oral prednisone (test preparation,5 mg) and prednisolone tablets (reference preparation,5 mg) using a randomized, two-period, two crossover, single-dose, fast and fed trial in 48 (24 in fast, 24 in fed) healthy the whole process of the study. Prednisone and prednisolone undergo interconversion in liver. On average, the bioavailability of prednisolone after oral prednisone is approximately 80% of that after prednisolone. And about 20% of prednisolone is converted to prednisone after administration of equivalent oral of prednisolone tablet. Food taken with prednisone or prednisolone tablets delays the time reach
The effect of prednisolone ingestion and acute exercise on lipocalin-2 and its variants in young men: a pilot randomised crossover study. Lipocalin-2 (LCN2) has three main variants; polyaminated (hLCN2) and non-polyaminated (C87A and R81E). The polyaminated form is proposed to positively influence energy control, whereas the non-polyaminated forms negatively impact energy control in mice exercise (90-95% heart rate reserve) after glucocorticoid or placebo ingestion. Blood was collected and analyzed for LCN2 and its variants levels at baseline, immediately, 60 min and 180 min post-exercise. Insulin sensitivity was assessed using hyperinsulinemic-euglycemic clamp. A main effect, increase in LCN2 was detected for prednisolone ingestion (overall treatment effect p = 0.001), but not LCN2
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): long-term results of a multicentre, single-a Intravascular large B-cell lymphoma (IVLBCL) is a rare type of extranodal large B-cell lymphoma for which prognosis is typically poor without
Changes in Adrenal Function and Insufficiency Symptoms After Cessation of Prednisolone. The widespread use of glucocorticoid (GC) therapy may result in GC-induced adrenal insufficiency (GIAI), but the prevalence and clinical implications remain uncertain. To ascertain the prevalence and symptoms of GIAI. Cross-sectional multicenter study at 3 Danish hospitals. Baseline data were collected March 2021 to March 2024 from an ongoing randomized clinical trial. Participants were patients with polymyalgia rheumatica and/or giant cell arteritis who were investigated a median (IQR) of 39 (25-62) days after planned cessation of prednisolone treatment. Prednisolone treatment a median (IQR) of 13 (10-20) months in duration. Primary outcome GIAI was defined as a stimulated plasma cortisol level less
Efficacy and Safety of Enzalutamide and Abiraterone Plus Prednisolone in Elder Castration-Resistant Prostate Cancer Patients: A Sub-Analysis From the ENABLE Study. Clinical trials rarely focus on elder patients with castration-resistant prostate cancer (CRPC), and data on the outcomes of second-generation androgen receptor signaling inhibitors (ARSIs) remain limited. The ENABLE study for prostate cancer was an investigator-initiated, multicenter, randomized controlled trial conducted in Japan to compare enzalutamide (ENZ) and abiraterone plus prednisolone (ABI). This sub-analysis was performed to evaluate the efficacy and the safety profiles between patients aged ≥ 75 (older) and < 75 years (younger), and then between the ENZ and ABI arms in the older and the younger cohort separately
Prednisolone prescribing practices for dogs in Australia. Although prednisolone is a routinely prescribed medication in dogs, there is a lack of information regarding prednisolone prescribing practices by veterinarians. This study aims to describe characteristics of dogs receiving prednisolone, disease processes treated, doses prescribed as well as to identify factors influencing the dose rate in Australia. The VetCompass Australia database was queried to identify dogs prescribed prednisolone between 1 July 2016 to 31 July 2018 (inclusive). A random sample of 2,000 dogs from this population were selected. Dog demographic data, prednisolone dose and indication for prescription were collated. Indicated dose for the condition treated was compared to prescribed dose. Multivariable linear regression
In RA, use of systemic glucocorticoids ≥5 mg/d (prednisolone-equivalent) was linked to MACE at 8.7 y. So H, Lam TO, Meng H, et al. Ann Rheum Dis. 2023;82:1387-1393.37487608.
Cost-effectiveness of Prednisolone to Treat Bell Palsy in Children: An Economic Evaluation Alongside a Randomized Controlled Trial Bell's palsy is the third most frequent diagnosis in children with sudden onset neurological dysfunction. The cost-effectiveness of treating Bell's palsy with prednisolone in children is unknown. We aimed to assess the cost-effectiveness of prednisolone in treating the trial were included (N=180). Interventions were oral prednisolone, or taste matched placebo administered for 10 days. Incremental cost-effectiveness ratio comparing prednisolone with placebo was estimated. Costs were considered from a healthcare sector perspective and included Bell's palsy related medication cost, doctor visits and medical tests. Effectiveness was measured using quality-adjusted life
Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol Abiraterone acetate plus prednisolone (herein referred to as abiraterone) or enzalutamide added at the start of androgen deprivation therapy improves outcomes restriction) had metastatic, histologically-confirmed prostate adenocarcinoma; a WHO performance status of 0-2; and adequate haematological, renal, and liver function. Patients were randomly assigned (1:1) using a computerised algorithm and a minimisation technique to either standard of care (androgen deprivation therapy; docetaxel 75 mg/m intravenously for six cycles with prednisolone 10 mg orally once per
Complex regional pain syndrome: diagnostic challenges and favorable response to prednisolone. Complex regional pain syndrome (CRPS), characterized by severe and disproportionate pain, is a rare and debilitating condition. Due to its rarity, evidence-based treatment guidelines remain limited, creating a challenge for clinicians. We present the case of a 20-year-old female with CRPS type 1 of the right hand. Her pain, initially triggered by a minor trauma, had persisted for three months. The patient demonstrated severe pain, swelling, hyperesthesia, and restricted range of motion. Despite multiple hospital visits, her symptoms did not improve until she was diagnosed with CRPS and treated with oral prednisolone. A dosage of 40 mg daily led to a dramatic response within 10 days. Our report
An open label non-inferiority randomized control trial evaluated alternate day prednisolone given daily during infections vs. levamisole in frequently relapsing nephrotic syndrome. Initial therapies for children with frequently relapsing nephrotic syndrome include alternate-day prednisolone that is given daily during infections, or levamisole. In this open label, non-inferiority trial, 160 patients, 2 to 18-years-old with frequent relapses, were randomly assigned to receive either prednisolone (0.5-0.7 mg/kg/alternate-day, given daily during infections), or levamisole (2-2.5 mg/kg/alternate-days) for one-year. Patients with relapses on alternate day prednisolone at over 1 mg/kg, prior use of potent steroid-sparing therapies, eGFR under 60 ml/min/1.73 m and significant steroid toxicity were